U.S. Nutraceuticals astaxanthin buy
This article was originally published in The Rose Sheet
Executive Summary
Ingredient research and manufacturing company acquires astaxanthin business of Redmond, Wash.-based La Haye Laboratories, Eustis, Fla. company announces Sept. 9. Business includes high-potency antioxidants astaZanthin and Zanthin, which are both used in skin care and dietary supplement products, company notes. Deal will allow La Haye Labs' core brand positioning to be leveraged by U.S. Nutraceuticals' "scientific technology, marketing strength and business development resources," La Haye says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.